Evidence map›Paper›PMID 34309235›Full record

ReviewCancer reports (Hoboken, N.J.)2022

Wilms tumor with Mulibrey Nanism: A case report and review of literature.

Karthik Upasana, Dhwanee Thakkar, Dheeraj Gautam, Manvinder Singh Sachdev, Anjali Yadav, Rohit Kapoor, Veena Raghunathan, Maninder Singh Dhaliwal, Kartikeya Bhargava, Sandhya Nair and 3 more

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Mulibrey Nanism: Clinical Spectrum and Molecular Pathogenesis.International journal of molecular sciences · 2026
    Review
  3. Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith-Wiedemann Syndrome and Other Predisposition Syndromes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Karthik UpasanaPediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India.
Dhwanee ThakkarPediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India.
Dheeraj GautamDepartment of Pathology, Medanta The Medicity, Gurgaon, Haryana, India.
Manvinder Singh SachdevDepartment of Pediatric Cardiology, Medanta The Medicity, Gurgaon, Haryana, India.
Anjali YadavPediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India.
Rohit KapoorPediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India.
Veena RaghunathanPediatric Intensive Care Unit, Department of Pediatrics, Medanta The Medicity, Gurgaon, Haryana, India.
Maninder Singh DhaliwalPediatric Intensive Care Unit, Department of Pediatrics, Medanta The Medicity, Gurgaon, Haryana, India.
Kartikeya BhargavaDepartment of Electrophysiology and Pacing, Heart Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Sandhya NairMedGenome Labs Ltd., Bangalore, Karnataka, India.
Jaiprakash SharmaDivision of Radiology, Medanta The Medicity, Gurgaon, Haryana, India.
Neha RastogiPediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India.ORCID 0000-0003-4699-6723
Satya Prakash YadavPediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India.ORCID 0000-0002-0507-1786
Medanta The Medicity · INSciGenom Labs (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMulibrey-Nanism (Muscle-liver-brain-eye Nanism = dwarfism; MUL) is a rare genetic syndrome. The underlying TRIM37 mutation predisposes these children to develop tumors frequently. In the largest published series of MUL, 8% patients were reported to develop Wilms tumor (WT). The published literature lacks data regarding the best treatment protocol and outcome of this cohort of children with WT and MUL. We report here a 2-year-old boy with WT and MUL and present a review of literature on WT in MUL. CASE: Our patient had associated cardiac problems of atrial septal defect, atrial flutter and an episode of sudden cardiac arrest. We managed him successfully with chemotherapy, surgery and multi-speciality care. He is alive and in remission at follow-up of 6 months.

conclusionA total of 14 cases (including present case) of WT have been reported in MUL and treatment details were available for six cases. They were managed primarily with surgery, chemotherapy with/without radiotherapy, and all achieved remission. The outcome data is available only for two cases, one has been followed up till 15 years post treatment for WT and other is our patient.

Indexed as

Kidney NeoplasmsMulibrey NanismWilms TumorChildChild, PreschoolHumansMaleNuclear ProteinsTripartite Motif ProteinsUbiquitin-Protein LigasesNuclear ProteinsTRIM37 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligasesatrial flutteratrial septal defectMulibrey NanismWilms tumor

Identifiers

PMID34309235
PMCPMC9124505
OpenAlexW3185930019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.